Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking like a program for "EXPIDITED DEVELOPEMENT" to begin April 1 2023 would be great for MYMD.
https://www.raps.org/news-and-articles/news-articles/2022/11/fda-announces-cmc-review-pilot-for-drugs-with-expe
Oramed reports Oravax study results!
https://oramed.com/oramed-subsidiary-oravax-reports-positive-preliminary-phase-1-data-for-its-oral-covid-19-vaccine/
WHAT MYMD NEEDS NOW IS EVIDENCE THAT MYMD-1 BLOCKS LONG COVID !!!!!
Just noticed on the internet that Supera Pharmaceuticals, Inc. is now listed as an "INACTIVE" company. This leaves me to conclude that MIRA1a Nutraceuticals, as a subsidiary of MYMD, is now taking over the job of seeking drug status for a marijuana like molecule they are calling "Mira 1a".
Just saw this !!!!! TAKE A LOOK !!!!!
https://mira1a.com/wp-content/uploads/2022/10/Opportunity_Mira_Pharma.pdf
SOUNDS GOOD! THANKS.
Have struggled with the patents in the hope of understanding more of what MYMD-1 can do other than limiting inflammation, but lack the background to grasp their complex explanations of the chemistry involved. In addition to the question of whether eliminating excess inflammation will result in resolving damage of previous excess inflammation, is the question of whether or not it would be desirable to prescribe MYMD-1 as soon as it is determined that excess inflammation is the major contributor to the disease condition, as seems to be the case in the current situation with young children being hospitalized in increased numbers!
Significant article today on inflammation (see nothing new), in a National Geographic ad, may account for the activity today in MYMD!
https://www.nationalgeographic.com/science/article/the-end-of-inflammation-new-approach-could-treat-dozens-of-diseases?rid=F94D92CC89D243DC9DF514AB5FC08E02&cmpid=org=ngp::mc=acq-email::src=ngp::cmp=acq_welcome_series::add=welcome1
The trial is specifically mentioned in the following news release.
https://www.americanpharmaceuticalreview.com/1315-News/578164-MyMD-Pharmaceuticals-Lead-Compound-MYMD-1-Shown-to-Suppress-a-Major-Cause-of-Death-in-COVID-19-in-Human-Cell-Study/
According to the info I have, the Johns Hopkins researchers should have completed testing of all approved Covid Induced depression subjects in the phase 2 study by 10/01/2022. If so, preparations to tabulate the results should be underway.
We are left to wonder if MyMD Pharma will provide any preliminary results before
the study ending date of 03/01/2023!
WHAT IS THIS!!!!!
https://fsdpharma.com/
Apple News has got the "Chronic Inflammation" story down pat, but seems to have no knowledge about MYMD-1! At least it's a start!
https://podcasts.apple.com/us/podcast/what-is-chronic-inflammation-how-does-it-damage-your-body/id976253083?i=1000556328595
OOPS! SORRY, WRONG BOARD!
OOPS! SORRY, WRONG BOARD!
Anyone ever heard of MyMD Pharmaceuticals!
https://www.mymd.com/
Anyone ever heard of MyMD Pharmaceuticals!
https://www.mymd.com/
Here's a company, DICE Therapeutics, up 50% today, that could eventually be a competitor, that rose on the basis of the results of a Phase 1 study that its small molecule, which blocks IL17, significantly reduced Psoriasis in the study.
https://www.dicetherapeutics.com/about/
Looks to me that MyMD is way ahead of them.
Comments and observations welcomed!
This board is near death! Let's hope that is about to change!!!!!
The previous list of private Florida companies with a connection to MYMD lists one called PSYCHEDELX Pharmaceuticals. It has a website https://psychedelxpharma.com/drug-development/
which mentions 2 potential drug candidates STACYBIN and KETAMIR which are also on the previous list. This is getting very interesting!
Here is a list of active Florida private companies, that have MYMD's suite address in a Johns Hopkins building, as their only address or one of their addresses.
MIRA1a Therapeutics ABETA Inc. MYVET Inc. NEMO LIFE SCIENCES Inc.
SETACYBIN Inc. COTIMINE Inc. KETAMIR Inc. OXYGENE Inc.
REVLIMIR Inc. TINA PHARMA Inc. ICENE Inc. MIRAVID Inc
DOPAMYNE Inc PSYCHEDELX Inc. ARICA Pharma Inc.
This list was difficult to compile, so there may be an error or 2. My impression is that each was created to represent a particular application of MYMD's molecules.
Here is the list of new, active companies affiliated with MYMD.
https://www.corporationwiki.com/p/2fhwnn/jonnie-williams#companies
FANTASTIC FIND, Sean !!!!! MYMD created at least a dozen new companies, most in 2021, and all with same corporate address as MYMD in the suite on the Johns Hopkins campus! None of them was MIRA1a Pharmaceuticals, but they created MIRAVID Inc.
How this relates to our investment in MYMD remains to be discovered, but each company seemed to be aimed at a specific application of MYMD's molecules!
MYMD-1 moves on to cohort 3, 900 mg level, in phase 2 life extension study with no problems so far, and expects efficacy data in 4th quarter 2022!
MYMD-1 moves on to cohort 3, 900 mg level, with no problems so far, and expects
At the very least I am expecting the following news releases by Xmas.
1. Early review of Covid 19 induced depression phase 2 study.
2. Update on 2nd dosage results in (sarcopenia) healthy life extension phase 2 study.
3. Results in both cohorts in Covid 19 vaccine pill study by Oramed.
4. Announcement of joint MYMD Pharma/Arthritis Foundation phase 2 study of
MyMD-1 vs Rheumatoid Arthritis.
Great find! Thanks for posting. Looks to be slightly cheaper at the moment than Pick's "Buy one, Get one free".
Here is an interesting article on "long Covid" that focuses on the possible causes. MYMD is currently conducting a Phase 2 study of Covid 19 induced depression being treated with MYMD-1. I have my fingers crossed that MYMD-1 will be shown to knock down the lingering inflammation that may be the cause of "long Covid" symptoms.
https://www.grid.news/story/science/2022/09/07/how-long-covid-studies-could-help-scientists-solve-the-long-unsolved-mystery-of-post-viral-illnesses/
The July 7 Oramed Letter To Shareholders updates the situation with the Oravax Covid 19 vaccine pill.
https://oramed.com/oramed-letter-to-shareholders/
Greatly appreciate your reply!
Desperately need help in understanding this morning's Form D filing with the SEC.
https://ih.advfn.com/stock-market/NASDAQ/mymd-pharmaceuticals-MYMD/stock-news/88944045/small-company-offering-and-sale-of-securities-with
Hope it is saying that the 9 officers and directors of MYMD are eventually acquiring 1.4+ million shares of MYMD @ $5.25 a share, but I can't figure it out!
On 7/26/22 MYMD Pharma announced they were advancing the Healthy Lifespan Phase 2 Trial from the 1st cohort (600 mg) to the next cohort (750 mg). As of today we have not had any info from the 2nd active Phase 2 study, Covid 19 induced depression!
It has occurred to me that any success in treating or eliminating said depression would indicate that the same results would likely be true for all forms of "long covid" as all are dependent on chronic inflammation. That result would quickly qualify MYMD-1 for the CTAP (Coronavirus Treatment Acceleration Program) to speed up MYMD-1's availability for use in fighting "long Covid". MYMD's Chief Scientific Officer, Adam Caplin, has been quoted as saying, "The importance of our upcoming Phase 2 trial(Covid 19 induced depression) can't be overstated", and I suspect he was referring to "long Covid" treatment.
Comments welcomed!
The Oramed website reports that the Oravax vaccine pill being trialed in South Africa for safety, tolerability, and effectiveness will be reporting Cohart 1 results in Q 3, '22 and Cohart 2 in Q 4, '22.
GOOD NEWS / BAD NEWS
Don't like the dilution, but we need the funds and it's not much compared to the $100,000,000 authorized!
Thanks for posting!
Looking like the fires been lit under MYMD!
ANOTHER WONDER DRUG JOINS THE FRAY!
https://www.healtheuropa.com/alzheimers-disease-is-plasticity-sciences-big-breakthrough/115915/
Very disappointed at the muted reaction to the mouse study news (currently down .02), though the volume is strong. You know who may be selling into uptrend to prevent what might have been a normal positive upmove.
The attached current video highlights the importance of inflammation in the development of ALZHEIMERS, but hasn't yet discovered MYMD-1.
https://www.nbcnews.com/health/aging/targeting-brain-inflammation-key-beating-alzheimer-s-disease-n1014121
Have been following this story since June 2009 when an option strategy I was using went awry, and I became an unwilling owner of shares of STSI, Star Scientific, and an eventual fan of Jonnie Williams Sr. through anatabine, Rock Creek Pharma, and now MYMD. After all these years of reading about many different medications, and slogging through countless patent applications, I have finally come to the conclusion that what MyMD Pharmaceuticals is trying to do is the most significant advance in human and mammalian health since the discovery of antibiotics.
And it is so simple! Inflammation is normal, but chronic inflammation can be disruptive and deadly. Modulate inflammation with MYMD-1, and you eliminate hundreds of diseases and other medical problems!